Table 2.
SVR Rates to Phase 3 Trials of IFN‐free AbbVie Regimens in Patients with HCV Genotype 1(see references 9, 10, 11, 12)
| Study (duration) | Patients | Treatment Regimen | SVR12 |
|---|---|---|---|
| PEARL‐II (12 weeks) | GT1b treatment‐experienced | AbbVie regimen + RBV (n = 88) | 97% |
| AbbVie regimen only (n = 91) | 100% | ||
| PEARL‐III (12 weeks) | GT1b treatment‐ naïve | AbbVie regimen + RBV (n = 210) | 99% |
| AbbVie regimen only (n = 209) | 99% | ||
| PEARL‐IV (12 weeks) | GT1a treatment‐ naïve | AbbVie regimen + RBV (n = 100) | 97% |
| AbbVie regimen only (n = 205) | 90% | ||
| TURQUOISE‐II (12 and 24 weeks) | GT1 treatment‐ naïve and treatment‐experienced with compensated cirrhosis | AbbVie regimen + RBV, 12 weeks (n = 208) | 92% |
| AbbVie regimen + RBV, 24 weeks (n = 172) | 96% | ||
| SAPPHIRE‐I (12 weeks) | GT1 treatment‐ naïve | AbbVie regimen + RBV (n = 473) | 96% |
| SAPPHIRE‐II (12 weeks) | GT1 treatment‐experienced | AbbVie regimen + RBV (n = 297) | 96% |
AbbVie regimen consists of ABT‐450/ritonavir (150 mg/100 mg) coformulated with Ombitasvir (ABT‐267) (25 mg), dosed once daily, and Dasabuvir (ABT‐333) (250 mg), dosed twice daily. RBV weight‐based dosing, twice daily.
Abbreviation: GT, genotype.